Prescription drug assistance program for the elderly.
Impact
The bill will significantly impact state laws concerning healthcare and assistance for senior residents by formalizing a structure to help diminish the financial burden of prescription medications. The program is expected to enhance access to necessary drugs for the elderly population, particularly those whose incomes may limit their ability to afford medications. The implementation of the program is set for January 1, 2027, following an effective date of July 1, 2026. This phased approach gives time for the completion of necessary administrative processes and funding allocations.
Summary
House Bill 1405 establishes a Prescription Drug Assistance Program for the elderly in Indiana. This program aims to offer financial assistance to residents aged 65 and older who are not recipients of Medicaid and who meet certain income criteria. Upon application, eligible individuals will receive a prescription drug card that allows them to purchase medications at reduced prices according to a set deductible, varying based on household income levels. The program is to be administered by the division of aging and will be funded through an established fund that collects rebates from pharmaceutical companies as well as appropriated state money.
Contention
Notable points of contention surrounding HB 1405 might include concerns about the sustainability of the funding for the program, given that it relies heavily on state appropriations and pharmaceutical rebates. Additionally, there may be debates regarding the eligibility requirements, particularly the income thresholds set for participation, which could potentially exclude lower-income elderly individuals who might also need assistance. Furthermore, the establishment of penalties for fraud associated with the program could spark discussions about enforcement and accountability mechanisms as outlined in the bill.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.